Quanterix and STRATEC announce strategic partnership
Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA(TM)) technology, and STRATEC Biomedical AG, a worldwide leader in the development and manufacture of automated analyzer systems, announced an agreement to co-develop and manufacture a fully-automated instrument for Quanterix's SiMoA technology for use in both the life sciences and in vitro diagnostics (IVD) markets. Quanterix expects to launch a life sciences instrument in 2013, followed by the commercialization of an IVD platform in 2014.
As part of the agreement, Quanterix will receive access to STRATEC's platform technology, which will be customized to both optimize and automate the advanced applications of Quanterix's SiMoA technology. STRATEC will receive payments, as well as a minority stake of approximately 7% in the share capital of Quanterix, upon the achievement of technological milestones. After completion of the development phase, STRATEC will manufacture and supply the system and Quanterix has committed to order an agreed minimum volume of systems.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.